Neuren shares jump on gains from priority voucher sale
Make us a preferred source
Make us a preferred source on Google
More news: Shares in Neuren Pharmaceuticals jumped more than 6% to $13.04 in early trading on the ASX after its US partner Acadia Pharmaceuticals agreed to sell the Rare Pediatric Disease priority review voucher (PRV) granted by the US FDA for US$150 million ($226 million).
The Australian company is entitled to a third of the proceeds.
Neuren to benefit from sale of FDA priority review voucher
The news: Neuren Pharmaceuticals will receive a third of the proceeds from the sale of a priority review voucher (PRV) granted by the US Food and Drug Administration (FDA).
The numbers: Neuren said its US partner Acadia Pharmaceuticals has agreed to sell the Rare Pediatric Disease PRV for USD150 million ($226 million).
The Australian company is entitled to a third of the proceeds.
The context: Neuren said the PRV was granted by the FDA following the approval of the Daybue drug that was launched in April 2023.
Under the FDA’s voucher program, a sponsor who receives an approval for a drug for a rare paediatric disease may qualify for a voucher that can be redeemed to receive priority review for a different product. The voucher can also be sold or transferred to another sponsor.
Acadia has exclusive rights to develop and commercialise globally Daybue, used for treatment of Rett Syndrome.
The source: ASX announcement
